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ay Moynihan and colleagues 
describe disease mongering 
as, “widening the boundaries 
of treatable illness in order to 
expand markets for those who sell 
and deliver treatments” [1]. In this 
article, I examine one aspect of disease 
mongering: activities ﬁ  nanced by 
drug companies to promote sales 
by expanding the pool of patients 
potentially treated by their products, 
when no beneﬁ  t in terms of reduced 
morbidity is likely. New diseases may 
be “created” or existing conditions 
redeﬁ  ned. In theory, these activities 
are covered by national laws governing 
drug promotion that forbid misleading 
or deceptive advertising. However, 
enforcement is piecemeal and largely 
ineffective. 
    Drug regulation remains limited 
in many parts of the world. In 2004, 
fewer than one-sixth of countries 
had a well-developed system of drug 
regulation, and one-third had little to 
no regulatory capacity [2]. Although 
89 countries (46%) reported active 
regulation of drug promotion, 
resources devoted to this work may be 
limited [3]. 
    Full direct-to-consumer advertising 
(DTCA) of prescription drugs is legal 
in only the United States and New 
Zealand. However, in many other 
countries, unbranded disease-oriented 
advertising (in which no drug names 
are mentioned, but patients are 
often advised to “see your doctor”) 
is increasingly common. The Dutch 
Health-Care Inspectorate reviewed 
28 product-speciﬁ  c marketing 
plans for prescription drugs, from 
ten companies, obtained through 
subpoenas from 1999 to 2002; 3.5% of 
their budgets were devoted to DTCA 
[4]. A market analyst reports that drug 
companies spent US$85 million on 
unbranded DTCA in Europe in 2004 
[5]. Spending is expected to reach 
US$345.5 million by 2008. In 2005, 
the Australia–US free trade agreement 
allowed unbranded advertising in 
Australian media to be linked to 
branded information on Web sites 
[6]. Canada introduced more lenient 
policies on unbranded advertising in 
1996, a shift that has occurred without 
legislative change [7]. 
    A claimed beneﬁ  t of disease-
awareness campaigns is that the public 
becomes more aware of untreated 
health problems and seeks effective 
care at an earlier stage, leading to 
better health [8]. For this to happen, 
the campaigns must address important 
health concerns, focus on patients likely 
to beneﬁ  t from diagnosis and treatment, 
and steer them towards appropriate 
care. For the individual patient, drug 
treatment is worth pursuing if potential 
beneﬁ  ts outweigh potential harm. But as 
healthier people are targeted, the added 
beneﬁ  t of drug treatment can become 
increasingly elusive.
    Limited Regulatory Oversight of 
Unbranded Disease-Awareness 
Adverts 
    The US Food and Drug Administration 
(FDA) published a guidance in 2004 
stating that unbranded adverts that are 
perceptually similar or otherwise linked 
to branded adverts are subject to FDA 
regulation, as are unbranded adverts 
by the manufacturer of the only drug 
in its class [9]. Otherwise, the FDA 
has no authority over the content of 
disease-oriented advertising, although 
it recommends responsible public 
health messages. The United Kingdom 
Medicines Health-Care Products 
Regulatory Agency has issued guidelines 
stating that the primary purpose of 
disease-awareness advertising must be 
health education on a disease and its 
management, not product promotion 
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  Box 1. Forms of Disease 
Mongering Used to Expand 
Drug Sales 
    •  Promotion of anxiety about future ill-
health in healthy individuals
  •  Inﬂ  ated disease prevalence rates 
    •  Promotion of aggressive drug 
treatment of milder symptoms and 
diseases
    •  Introduction of questionable new 
diagnoses—such as PMDD or social 
anxiety disorder—that are hard to 
distinguish from normal life
  •  Redeﬁ  nition of diseases in terms of 
surrogate outcomes (i.e., osteoporosis 
becomes a disease of low bone density 
rather than fragility fractures)
    •  Promotion of drugs as a ﬁ  rst-line 
solution for problems previously not 
considered medical, such as disruptive 
classroom behaviour or problematic 
sexual relationships.  PLoS Medicine  |  www.plosmedicine.org 0462
[10]. However, the Medicines Health-
Care Products Regulatory Agency 
allowed Novartis’ advertising on fungal 
nail infections (onychomycosis), 
which stressed high prevalence and 
infectiousness and guided viewers to 
prescription drugs, including Novartis’ 
drug terbinaﬁ  ne (Lamisil) [10]. 
    In the Netherlands, a similar 
Novartis campaign for onychomycosis 
prompted the Dutch government to 
take Novartis to court for illegal DTCA. 
The government lost the case as neither 
the product nor the manufacturer was 
named [11]. ‘t Jong and colleagues 
subsequently analyzed the effects of 
the campaign on primary care, using 
administrative data covering 150 
practices. They studied the changes in 
rates of prescriptions of oral terbinaﬁ  ne 
(Lamisil) and itraconazole (Sporanox, 
a competitor to Lamisil), and the 
onychomycosis consultation rate, before 
and after the start of the campaign. 
Both onychomycosis consultations 
and prescriptions for terbinaﬁ  ne 
(Lamisil) grew, whereas prescriptions 
for the competitor drug declined [12]. 
Thus, an unbranded campaign had 
a brand-speciﬁ  c effect on sales, most 
likely because of concurrent branded 
promotion to physicians. ‘t Jong et al. 
noted the effects of promotion of a 
condition that is largely cosmetic (it 
usually causes no pain or suffering) on 
physicians’ workload. 
    Promoting Sales through Fear 
of Death 
    Pﬁ  zer, the manufacturer of Lipitor 
(atorvastatin), ran a campaign in 
France and Canada in 2003 with print 
adverts that used images of a tagged toe 
of a corpse (the Canadian campaign 
was in association with the Canadian 
Lipid Nurse Network and the Canadian 
Diabetes Association) (Figure 1). On 
television, a youthful, healthy man 
died suddenly of a heart attack, leaving 
his family devastated with grief. The 
message of these two adverts was that 
cholesterol testing and treatment could 
prevent premature death from heart 
attacks in healthy people. This was at 
odds with existing scientiﬁ  c evidence: 
a 2003 meta-analysis of cholesterol-
lowering drugs in primary prevention 
found no difference in mortality 
between drug and placebo [13]. 
    Jonathan Quick and colleagues 
at the World Health Organization 
raised concerns in the   Lancet   that the 
adverts misinformed the public about 
cardiovascular risks and could lead 
to harm from medically unjustiﬁ  ed 
drug use [14]. They argued that 
governments should take a more active 
role in regulating disease-awareness 
campaigns to prevent misleading 
information from reaching the public. 
Complaints in Canada, which included 
the   Lancet   letter, resulted in no 
regulatory action [15]. A subsequent 
advert shows a man walking down a 
city street, unaware that he is about 
to be charged by a rhinoceros. The 
tagline is the following: “Living with 
high cholesterol, you never know 
what’s around the corner.” The text 
stresses the risk of death from heart 
attacks. The only risk factor discussed is 
cholesterol. 
    Disease-awareness advertising is 
often the visible face of broader 
commercial inﬂ  uences. Eight of the 
nine authors of the US cholesterol 
treatment guidelines released in 2004 
had ﬁ  nancial links to manufacturers 
(Cleeman was the only member of the 
panel with no such ties; see http:⁄⁄www.
nhlbi.nih.gov/guidelines/cholesterol/
atp3upd04_disclose.htm) [16]. These 
guidelines extended treatment of high 
cholesterol to patient groups in which a 
morbidity and mortality advantage had 
not been established. A Pﬁ  zer ﬁ  nancial 
report on atorvastatin (Lipitor) states, 
“There continues to be an opportunity 
for further growth of the cholesterol-
lowering market....Evolving treatment 
guidelines continue to encourage the 
broad use of statin therapy” [17]. 
  Hormone  Replacement  Therapy 
and Menopause: An Ongoing Saga 
    Promotion of hormone replacement 
therapy (HRT) for disease prevention 
is a key example of disease mongering 
linked to drug sales. Women learned 
to view menopause in terms of 
increased health risks that could be 
prevented with HRT. The ﬁ  rst long-
term randomized controlled trial of 
HRT in healthy women, the Women’s 
Health Initiative, found a 1% increase 
in absolute risks for serious harm over 
ﬁ  ve years, mainly due to cardiovascular 
adverse effects [18]. The negative 
public health impact of HRT use 
by millions of women worldwide is 
likely to have been considerable. 
Regulatory agencies have changed 
labelling to warn potential users of 
serious risks and to advise limiting use 
to short-term symptomatic treatment, 
but have taken no broader action to 
review marketing of drugs for disease 
prevention. 
    On 28 December 2005, the ﬁ  rst hit 
on a Google search on “menopause 
and estrogen deﬁ  ciency” was a Merck 
Web site promoting an estrogen patch, 
and linking postmenopausal estrogen 
deﬁ  ciency to reduced performance, 
ﬁ  ne motor skills, memory, and a 
reduction in “planned, targeted, 
ﬂ  exible and adaptable thought” [19].
    In 2006, a handbook for journalists, 
called   The Journalist’s Menopause 
Handbook  , which was funded by Wyeth 
Canada and produced by a medical 
society (the Society of Obstetricians 
and Gynaecologists of Canada), fails to 
mention increased risks of strokes, heart 
attacks, pulmonary emboli, or symptoms 
of probable dementia associated with 
HRT [20]. The magnitude of breast 
cancer risk is described as no greater 
than lifestyle-associated risks. Hot 
ﬂ  ushes, mood and memory, appearance 
(wrinkles), sleep disturbances, bladder 
control, and sexual changes are listed 
as menopausal symptoms. Short-term 
HRT for moderate to severe symptoms 
is recommended as safe and effective, 
with “short-term” deﬁ  ned as up to 
ﬁ  ve years [20]. Beyond the lack of 
established link between wrinkles and 
menopause (rather than ageing per se), 
is HRT really a reasonable treatment 
for wrinkles, given the cardiovascular, 
cancer, and dementia risks? 
    Lower Thresholds for Symptomatic 
Treatment and Public Health 
    Mamdani and colleagues found that 
following the launch of celecoxib 
(Celebrex) and rofecoxib (Vioxx), 
more elderly patients in Ontario 
DOI: 10.1371/journal.pmed.0030198.g001
  Figure 1.   Disease-Awareness Campaign 
Sponsored by Pﬁ  zer, the Manufacturer of 
Lipitor
   (Image  copyright:  Pﬁ  zer Canada Inc./Making 
the Connection. All rights reserved.) 
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were treated with nonsteroidal anti-
inﬂ  ammatory drugs (NSAIDs) than 
previously [21]. The increase was 
attributable to use of Cox-2 inhibitors 
by people not previously taking 
NSAIDs. Paradoxically, although these 
newer drugs were promoted for greater 
gastrointestinal safety, Mamdani and 
colleagues found that approximately 
650 more hospitalizations for 
gastrointestinal bleeds occurred per 
year after the drugs’ introduction. In 
their conclusion, the authors stated 
the following: “Although we cannot 
prove causation, we believe that 
the striking temporal correlation, 
biological plausibility, and lack of any 
other trends that would explain the 
association strongly suggest that the two 
events are directly related” [21].
    Another heavily promoted class of 
drugs are the proton pump inhibitors. 
Bashford and colleagues analyzed why 
patients were prescribed proton pump 
inhibitors during a ﬁ  ve-year period in 
which prescribing increased 10-fold. 
By 1995, 46% of prescriptions were for 
off-label uses, mainly milder problems 
[22]. In 2004, researchers found a link 
between use of proton pump inhibitors 
and higher risks of   Clostridium difﬁ  cile   
infection in hospitalized patients [23]. 
A US magazine advertisement for 
esomeprazole (Nexium) in November 
2005 (e.g., printed in   Family Circle  ), a 
year after this study, warns readers that 
“something could be brewing” beneath 
their heartburn. A distressed woman 
is shown with a red scarf around her 
neck, and on the scarf is the following 
statement: “Behind this scarf acid could 
be burning the lining of her esophagus.” 
The advert quotes a high rate of erosive 
esophagitis among people with acid 
reﬂ  ux, one in three, based on data on 
ﬁ  le at AstraZeneca. Although the advert 
contains the disclaimer that “only a 
doctor can determine if you have this 
condition,” the image of distress and the 
larger headlines—such as “Acid reﬂ  ux 
disease can damage your esophagus” 
and “Nexium heals the damage”—
convey the message to be anxious about 
heartburn and consider it a possible sign 
of more serious disease. Like many US 
adverts, this one offers a free trial. 
  Questionable  New  Indications
    Regulatory agencies have differed in 
their response to manufacturers’ bids 
to market selective serotonin reuptake 
inhibitor (SSRI) antidepressants for 
“premenstrual dysphoric dysfunction” 
(PMDD). Business analysts linked 
the launch of the ﬁ  rst drug in the 
US for this indication, ﬂ  uoxetine 
(Sarafem), to Eli Lilly’s pending loss 
of patent protection for Prozac (also 
ﬂ  uoxetine) [24].
    The European Medicines Evaluation 
Agency refused to approve drugs 
for PMDD, raising concerns that 
women “with less severe pre-menstrual 
symptoms might erroneously receive 
a diagnosis of PMDD resulting in 
widespread inappropriate short- and 
long-term use of ﬂ  uoxetine” [25]. The 
US and Australia have approved SSRIs 
for PMDD, but Australia does not cover 
their costs [26].
    Soon after Sarafem’s launch, the FDA 
judged a TV advert to violate US law 
because it failed to distinguish clearly 
between PMDD and premenstrual 
syndrome [27]. A US community survey 
of women aged 14–24 found a 6% 
prevalence of PMDD. An additional 
19% were “near-threshold” cases 
[28]. This survey likely overestimated 
PMDD, as classiﬁ  cation was based 
on recall rather than daily symptom 
diaries (and most women were only 
mildly impaired), but the high “near-
threshold” prevalence highlights the 
proﬁ  tability of broadening diagnostic 
boundaries [29].
    Disease Claims in US DTCA: 
A Mixed Regulatory Response 
    Unlike many countries that rely 
primarily on industry self-regulation, 
the FDA regulates prescription drug 
promotion directly. Letters of violation 
to manufacturers are posted on the 
FDA Web site, with detailed rationales 
for regulatory decisions [30]. Of the 
51 letters sent to companies in 2004 
to mid-December 2005, 21 were either 
on DTCA exclusively (  n   = 15) or on 
both DTCA and promotion for health 
professionals (  n   = 6). For 15 out of 
21 (71%) letters, reviewers from the 
FDA’s Division of Drug Marketing, 
Advertising, and Communications 
raised concerns related to disease 
mongering (Table 1). These concerns 
often consisted of (1) off-label 
promotion broadening approved 
indications and (2) misrepresentation 
of disease so as to exaggerate treatment 
effectiveness.
    Many examples also exist of disease 
mongering in US DTCA that has not 
been subject to regulation. In a recent 
article in   PLoS Medicine  , Lacasse and 
Leo reviewed the evidence supporting 
the hypothesis that depression is 
caused by a serotonin deﬁ  ciency, 
concluding that a lack of evidence 
exists to support this hypothesis [31]. 
They questioned the FDA’s lack of 
attention to the claims in SSRI adverts 
for antidepressants that depression 
and anxiety disorders are caused by a 
chemical imbalance in the brain. The 
Irish regulatory agency has prohibited 
GlaxoSmithKline from making similar 
claims to support the use of paroxetine 
(Paxil) [32]. 
    Kravitz and colleagues found more 
broadly that patient requests for 
advertised medicines could lead to 
off-label antidepressant prescribing 
for “adjustment disorder,” a disorder 
involving temporary distress due 
to a troubling life situation that 
rarely requires drug treatment [33]. 
Standardized patients received 
antidepressant prescriptions just 
over half the time if they requested 
the advertised antidepressant Paxil, 
whether they had symptoms of 
depression or adjustment disorder. 
If patients had not requested a 
drug, physicians were much less 
likely to prescribe antidepressants 
for adjustment disorder. This study 
provides experimental evidence 
of a link between patient requests 
for medicines and unnecessary 
medicalization. 
    Conclusion: Is a More Robust 
Regulatory Response Needed? 
    Box 1 summarizes the types of disease-
mongering activities companies can use 
to stimulate drug sales, including those 
described above. 
    The rationale for regulation of 
drug promotion is health protection, 
encouragement of appropriate 
medicine use, and prevention of 
deceptive advertising. The European 
community code on medicinal 
products for human use states that 
advertising of medicinal products 
“must encourage the rational use of the 
product and may not be misleading” 
[34]. Canada’s Food and Drugs Act 
prohibits advertising of a drug that 
is “false, misleading or deceptive 
or is likely to create an erroneous 
impression regarding its character, 
value, quantity, merit or safety” [35]. 
The World Health Organization’s 
Ethical Criteria for Medicinal Drug 
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  Table 1.   FDA Letters of Violation on Consumer-Directed Advertising, January 2004 to mid-December 2005   
Brand Product Indication Key Violations Identiﬁ  ed 
in FDA Letter
What the FDA Said about the Disease-Related Aspects of 
the Adverts
Atrovent, 
Combivent
Ipratropium, 
ipratropium/
albuterol
Chronic obstructive 
pulmonary disease 
Unsubstantiated effectiveness 
claims
Adverts “suggest that anticholinergics are essential for the treatment 
of COPD [Chronic obstructive pulmonary disease], and that COPD 
is not appropriately treated without an anticholinergic. This is 
false or misleading, because COPD can be treated without using 
anticholinergics” (http://www.fda.gov/cder/warn/2004/Atrovent1.pdf)
Celebrex, Bextraa Celecoxib, 
valdecoxib
Arthritis Omits risks; unsubstantiated 
effectiveness and superiority 
claims 
Television infomercial “overstates the effectiveness of the drugs while 
minimizing, by complete omission, the risks” (http://www.fda.gov/cder/
warn/2005/12560-letter.pdf)
Effexora Venlafaxine Depression False and misleading 
effectiveness and safety claims
Radio advert “fails to communicate important characteristics necessary 
to distinguish between major depressive disorder and variations of 
normal daily functioning” (http://www.fda.gov/cder/warn/2004/Effexor.
pdf)
Enbrel Etanercept Plaque psoriasis Broadens indication; overstates 
effectiveness
Television advert gives impression that “Enbrel completely clears skin 
with psoriasis…To our knowledge, Enbrel has not been shown to 
provide complete clearing of psoriatic skin” (http://www.fda.gov/cder/
warn/2005/Enbrelwl.pdf)
Kaletra Lopinavir/ritonavir HIV/AIDS Overstates effectiveness; omits 
indications and risk information
Advert gives a “misleading impression concerning the effectiveness of 
Kaletra” (http://www.fda.gov/cder/warn/2004/12810Kaletra.pdf)
Levitra Vardenaﬁ  l Impotence Unsubstantiated implied 
superiority 
Adverts “suggest that Levitra is superior to other treatments for ED 
[erectile dysfunction]…FDA is not aware of substantial evidence or 
substantial clinical experience demonstrating that Levitra is superior to 
other ED treatments” (http://www.fda.gov/cder/warn/2005/Levitra.pdf)
Muse Alprostadil Impotence Omits and minimizes risks; fails 
to mention urethral insertion 
“it is misleading to claim that MUSE will provide a ‘more normal and 
spontaneous sexual lifestyle’ or ‘allow the spontaneity that you and 
your sexual partner desire,’ when patients must follow at least 12 
distinct steps to administer MUSE correctly” (http://www.fda.gov/cder/
warn/2004/Macmis12039.pdf)
Paminea Methscopolamine Peptic ulcer 
(adjunct)
Omits risks, misrepresents 
safety, and promotes off-label 
use 
Patient brochure and Web site contain “unsubstantiated effectiveness 
claims” (http://www.fda.gov/cder/warn/2004/12413.pdf)
Paxil Paroxetine Social anxiety 
disorder
Broadens indication; minimizes 
serious risks
Advert misleads because it ”suggests that   anyone  experiencing anxiety, 
fear, or self-consciousness in social or work situations is an appropriate 
candidate for Paxil CR” (http://www.fda.gov/cder/warn/2004/
MACMIS12439.pdf)
Quadramet Samarium 
lexidronam
Osteoblastic 
metastic bone 
lesions (pain)
Overstates effectiveness; omits 
or minimizes risks
Adverts “imply that Quadramet is more effective in treating cancer 
pain and more beneﬁ  cial to patients receiving the drug than has been 
demonstrated by substantial evidence or substantial clinical experience” 
(http://www.fda.gov/cder/warn/2005/Quardramet_wl.pdf)
Seasonale Levonorgestrel/
ethinyl estradiol
Contraception Omits and minimizes risks TV advert “fails to reveal that (a) patients using Seasonale may 
experience breakthrough bleeding or spotting for up to a year, (b) the 
breakthrough bleeding may be up to the amount similar to a regular 
period” (http://www.fda.gov/cder/warn/2004/12748.pdf)
Strattera Atomoxetine Attention deﬁ  cit 
disorder
Broadens indication; minimizes 
risks
“This ad is concerning from a public health perspective because by 
failing to adequately communicate the Attention-Deﬁ  cit Disorder 
(ADD) indication for Strattera, it potentially broadens the use of the 
drug beyond the indicated patient population, while also minimizing 
the serious risks associated with the drug” (http://www.fda.gov/cder/
warn/2005/strattera.pdf)
Tracleera Bosentan Pulmonary arterial 
hypertension
Unsubstantiated superiority 
claims; broadens indication
“…the statement that PAH [pulmonary arterial hypertension] was 
‘invariably fatal’ before Tracleer implies that a survival beneﬁ  t has been 
shown for PAH patients who receive Tracleer therapy…FDA is not aware 
of substantial evidence or substantial clinical experience demonstrating 
a survival beneﬁ  t for Tracleer” (http://www.fda.gov/cder/warn/2005/
Tracleer_wl.pdf)
Viagra Sildenaﬁ  l Impotence Broadens indication; fails to 
disclose indication and risks
TV advert contains “unsubstantiated effectiveness claims” (http://www.
fda.gov/cder/warn/2004/12726.pdf)
Viramune Nevirapine HIV/AIDS Fails to disclose limits on 
indication; minimizes risks
“print ad is misleading because it fails to present risk information 
with…prominence and readability”(http://www.fda.gov/cder/
warn/2004/12717.pdf)
 aViolations involved materials targeting consumers and health professionals.
  DOI:  10.1371/journal.pmed.0030198.t001 
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Promotion states that advertisements, 
“…should not take undue advantage of 
people’s concern for their health” [36]. 
    Disease mongering by deﬁ  nition 
creates erroneous impressions of the 
condition a product aims to treat and 
the merit and safety of treatment, and 
frequently provokes undue anxiety or 
exaggerates prevalence rates. Many 
of the activities in Box 1 are off-label 
promotions. 
    The prohibition of DTCA is 
consistent with regulatory aims 
to protect health and encourage 
appropriate medicine use. Unbranded 
disease-awareness campaigns for the 
condition a manufacturer’s drug 
aims to treat are a form of DTCA. If 
these adverts are allowed under laws 
guaranteeing commercial freedom 
of expression, a regulatory rationale 
remains to (1) de-link them from 
suggestions to “ask your doctor” 
for a treatment and (2) to insist on 
prescreening of adverts by a government 
agency to ensure conformity with 
the law before they are broadcast or 
printed. Similarly, drug company 
funding of media promotions aiming 
to stimulate sales should be subject to 
the same regulatory control as direct 
advertising.
    Better deﬁ  nitions are needed of the 
indications drugs are approved to treat, 
to ensure consistency with assessed 
outcomes in premarket trials. Evidence 
of beneﬁ  t should be based on clinical 
outcomes, and greater caution is 
needed in introducing new diagnoses. 
    A key question is whether there 
is sufﬁ  cient political will among 
government regulatory agencies to 
better enforce existing regulations 
governing drug promotion or to 
introduce new solutions. Most 
regulatory agencies fail to treat 
regulation of drug promotion as a 
public health concern. Unless this 
changes, the public can expect more 
unfettered disease mongering warning 
them that without the latest treatment, 
life will be grim indeed.   
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